Through comparing hub common susceptibility genes and target genes of available drugs, we found that IL2RA and HLA-DRB1 that were identified as hub common susceptibility genes were the targets of daclizumab and glatiramer acetate, respectively, which were approved drugs of MS. Here, IL2RA is linked to myeloid sarcoma.